Clinical-stage biotechnology company Antibe Therapeutics Inc (TSX:ATE) (OTCQX:ATBPF) announced on Thursday that it has received approval from Health Canada to initiate a pharmacokinetic/pharmacodynamic (PK/PD) study for otenaproxesul's faster-absorbing formulation for acute pain management.
This study is slated to begin in October and is designed to determine the dosages for the Phase II trial.
"With this approval, we're excited to start the first-in-human study of otenaproxesul's new formulation -- and to be on track to launch the Phase II trial in calendar Q1 2024," said Antibe CEO Dan Legault.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA